Drug intelligence / Profile preview

pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepiride

Development stage
Unknown
Lead developer
Changzhou Qianhong Biopharma
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral
01

Overview

This is a **combination drug** composed of five active pharmaceutical ingredients: **pancreatin**, **oryz-aspergillus enzyme**, **acarbose**, **metformin**, and **glimepiride**. - **Pancreatin** and **oryz-aspergillus enzyme** are digestive enzymes designed to enhance gastrointestinal digestive function, commonly used in the management of dyspepsia and postprandial discomfort. Clinical studies show that the combined use of oryz-aspergillus enzyme and pancreatin tablets is effective in improving symptoms of dyspepsia and functional digestive disorders, with a favorable safety profile[1][3][7]. - **Acarbose** is an alpha-glucosidase inhibitor, which delays carbohydrate absorption in the gut, thereby blunting postprandial blood glucose spikes. It is commonly used to improve glycemic control in type 2 diabetes, especially in combination with other oral antidiabetic agents[2][4][8]. - **Metformin** is a biguanide that reduces hepatic glucose production and increases peripheral glucose uptake and utilization. It is the first-line therapy for type 2 diabetes due to its glycemic efficacy, weight neutrality, and cardiovascular safety[2][4][6]. - **Glimepiride** is a sulfonylurea that stimulates pancreatic beta cells to secrete insulin, leading to a reduction in blood glucose levels. It is frequently combined with metformin and/or other oral antidiabetic agents in type 2 diabetes for synergistic glycemic effect[6][8]. This combination targets both **digestive dysfunction (such as dyspepsia, maldigestion, and functional gastrointestinal symptoms)** and **hyperglycemia in type 2 diabetes mellitus**. The rationale is to address both gastrointestinal comfort and comprehensive glycemic control, particularly in elderly patients or those with concomitant digestive and metabolic disorders. While individual pairings of these ingredients are widely used and studied, there is limited evidence on the fixed-dose combination of all five in a single pharmaceutical product.

Brand names
CreonCombizymGlucobayGlucophageAmaryl
Other names
pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepirde-Changhai Hospital
02

Targets

Sucrase-IsomaltaseAMY (Pancreatic alpha-amylase)SUR1 (Sulfonylurea receptor 1)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepiride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepiride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call